Elixiron Immunotherapeutics (China) Ltd announced that it has raised $27 million in a round of funding led by new investor Pangu Capital and returning investor Taiwania Capital on August 23, 2021. The transaction included participation from new investors DCI Partners, Mega International Commercial Bank, Fubon Financial Holdings Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.